Add Alkem Laboratories, target price Rs 6,180: HDFC Securities

 15 Nov 2024 09:11 AM

HDFC Securities recommends buying shares of Alkem Laboratories. They set a target price of Rs 6,180. The current market price is Rs 5,535. Alkem Laboratories' recent performance was slightly below expectations. However, the company expects growth in the Indian pharmaceutical market and improved profitability. HDFC Securities believes Alkem Laboratories will experience steady growth in the coming years.

ALKEM LABS: CO EXPECTS PRODUCTION TO BEGIN BY Q4 TO Q1 OF NEXT FINANCIAL YEAR, WITH NO SIGNIFICANT DELAY REPORTED AS OF NOW || ANOTHER PRODUCT LAUNCH IS EXPECTED IN Q3, WHICH HAS RECEIVED CGT WITH VANITY DAYS EXCLUSIVITY - CONCALL UPDATE

 14 Nov 2024 08:51 AM

ALKEM LABS: CO EXPECTS PRODUCTION TO BEGIN BY Q4 TO Q1 OF NEXT FINANCIAL YEAR, WITH NO SIGNIFICANT DELAY REPORTED AS OF NOW || ANOTHER PRODUCT LAUNCH IS EXPECTED IN Q3, WHICH HAS RECEIVED CGT WITH VANITY DAYS EXCLUSIVITY - CONCALL UPDATE

ALKEM LABS: CO IS GUIDING FOR AN IMPROVEMENT IN EBITDA MARGINS BY AT LEAST 100 BASIS POINTS EVERY YEAR || CO AIMS TO IMPROVE THE EBITDA MARGIN IN THE U.S. BUSINESS TO BE CLOSER TO THE OVERALL EBITDA MARGIN, WHICH IS EXPECTED TO BE AROUND 18.5% TO 19% - CONCALL UPDATE

 14 Nov 2024 08:49 AM

ALKEM LABS: CO IS GUIDING FOR AN IMPROVEMENT IN EBITDA MARGINS BY AT LEAST 100 BASIS POINTS EVERY YEAR || CO AIMS TO IMPROVE THE EBITDA MARGIN IN THE U.S. BUSINESS TO BE CLOSER TO THE OVERALL EBITDA MARGIN, WHICH IS EXPECTED TO BE AROUND 18.5% TO 19% - CONCALL UPDATE

ALKEM LABS: CO IS MAINTAINING ITS OVERALL GROWTH GUIDANCE OF AROUND 8% TO 9% FOR THE DOMESTIC MARKET || CO EXPECTS MID-SINGLE DIGIT KIND OF GROWTH ON THE TOP-LINE - CONCALL UPDATE

 14 Nov 2024 08:48 AM

ALKEM LABS: CO IS MAINTAINING ITS OVERALL GROWTH GUIDANCE OF AROUND 8% TO 9% FOR THE DOMESTIC MARKET || CO EXPECTS MID-SINGLE DIGIT KIND OF GROWTH ON THE TOP-LINE - CONCALL UPDATE

Market Trading Guide: Tata Power, Alkem Labs among 5 stock recommendations for Thursday

 13 Nov 2024 08:55 PM

FII selling, weak corporate earnings, and rising domestic inflation led to a 1000-point drop in the Sensex on Wednesday. Concerns over US policy actions and trade impacts on the global economy are contributing to market jitters and a stronger US dollar.

Alkem Labs Q2 Results: Net profit rises 11% to Rs 689 crore

 13 Nov 2024 07:44 PM

Alkem Laboratories on Wednesday posted a 11% year-on-year (y-o-y) jump in net profit to Rs 689 crore in Q2FY25 led by growth in domestic formulation sales.

ALKEM LAB: H1 FY25 EBITDA MARGIN AT 21% VS FY25 GUIDANCE OF 18%

 13 Nov 2024 01:46 PM

ALKEM LAB: H1 FY25 EBITDA MARGIN AT 21% VS FY25 GUIDANCE OF 18%

ALKEM LAB: US SALES FALL 22% VS EST 4% DECLINE

 13 Nov 2024 01:28 PM

ALKEM LAB: US SALES FALL 22% VS EST 4% DECLINE

ALKEM LAB: Q2 REVENUE 34.1B RUPEES VS 34.4B (YOY)

 13 Nov 2024 01:07 PM

ALKEM LAB: Q2 REVENUE 34.1B RUPEES VS 34.4B (YOY)

ALKEM LAB: Q2 EBITDA 7.5B RUPEES VS 7.47B (YOY) || Q2 EBITDA MARGIN 22.04% VS 21.71% (YOY)

 13 Nov 2024 01:07 PM

ALKEM LAB: Q2 EBITDA 7.5B RUPEES VS 7.47B (YOY) || Q2 EBITDA MARGIN 22.04% VS 21.71% (YOY)